The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients

被引:19
作者
Christersson, Christina [1 ]
Lindahl, Bertil [1 ,2 ]
Berglund, Lars [2 ]
Siegbahn, Agneta [3 ]
Oldgren, Jonas [1 ,2 ]
机构
[1] Uppsala Univ, Dept Med Sci, Cardiol, S-75185 Uppsala, Sweden
[2] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden
[3] Uppsala Univ, Dept Med Sci, Clin Chem, Uppsala, Sweden
关键词
D-dimer; heart failure; myocardial infarction; thrombin; thromboembolism; THROMBIN GENERATION; MARKERS; THROMBOLYSIS; POPULATION; WARFARIN; HEPARINS; AMI;
D O I
10.1080/03009734.2017.1407849
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Despite improved treatment of myocardial infarction (MI), real-world patients still suffer substantial risk for subsequent cardiovascular events. Little is known about coagulation activity shortly after MI and whether coagulation activity markers may identify patients at increased risk despite contemporary treatment. Objective: To evaluate D-dimer concentration and thrombin generation potential shortly after discharge after MI and evaluate if these markers could predict the risk of future cardiovascular and bleeding events. Methods: Unselected MI patients (n = 421) were included in the observational REBUS study (NCT01102933) and followed for two years. D-dimer concentrations, thrombin peak, and endogenous thrombin potential (ETP) were analyzed at inclusion (3-5 days after MI) and at early follow-up (after 2-3 weeks). Results: Seventy-five patients (17.8%) experienced the composite endpoint (all-cause death, MI, congestive heart failure, or all-cause stroke), and 31 patients (7.4%) experienced a clinically relevant bleeding event. D-dimer concentrations at early follow-up were associated with the composite endpoint (HR [per SD increase] 1.51 [95% CI 1.22-1.87]) and with clinically relevant bleeding (HR [per SD increase] 1.80 [95% CI 1.32-2.44]). Thrombin generation potential was not significantly associated with either the composite endpoint or with clinically relevant bleeding. Higher thrombin peak and ETP at early follow-up were both inversely associated with stroke (HR [per SD increase] 0.50 [95% CI 0.30-0.81] and 0.43 [95% CI 0.22-0.83], respectively). Conclusion: In unselected MI patients treated according to contemporary guidelines, D-dimer measurements may identify patients at increased risk of new cardiovascular and bleeding events. The inverse association of thrombin generation potential and risk of stroke has to be further investigated.
引用
收藏
页码:224 / 233
页数:10
相关论文
共 34 条
[1]  
[Anonymous], 2011, SWEDEHEART annual report
[2]   Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis [J].
Barrett, Yu Chen ;
Wang, Jessie ;
Knabb, Robert ;
Mohan, Puneet .
THROMBOSIS AND HAEMOSTASIS, 2011, 105 (01) :181-189
[3]   D-Dimer Assays in Diagnosis and Management of Thrombotic and Bleeding Disorders [J].
Bates, Shannon M. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2012, 38 (07) :673-682
[4]   Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale, clinical trial [J].
Björklund, E ;
Lindahl, B ;
Stenestrand, U ;
Swahn, E ;
Dellborg, M ;
Pehrsson, K ;
Van De Werf, F ;
Wallentin, L .
AMERICAN HEART JOURNAL, 2004, 148 (04) :566-573
[5]   Early Atherosclerosis Exhibits an Enhanced Procoagulant State [J].
Borissoff, Julian Ilcheff ;
Heeneman, Sylvia ;
Kilinc, Evren ;
Kassak, Peter ;
Van Oerle, Rene ;
Winckers, Kristien ;
Govers-Riemslag, Jose W. P. ;
Hamulyak, Karly ;
Hackeng, Tilman M. ;
Daemen, Mat J. A. P. ;
Ten Cate, Hugo ;
Spronk, Henri M. H. .
CIRCULATION, 2010, 122 (08) :821-U145
[6]   Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment [J].
Vibeke Bratseth ;
Alf-Åge Pettersen ;
Trine B Opstad ;
Harald Arnesen ;
Ingebjørg Seljeflot .
Thrombosis Journal, 10 (1)
[7]   Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment [J].
Brodin, E. ;
Seljeflot, I. ;
Arnesen, H. ;
Hurlen, M. ;
Appelbom, H. ;
Hansen, J. B. .
THROMBOSIS RESEARCH, 2009, 123 (04) :573-579
[8]   Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial [J].
Christersson, Christina ;
Oldgren, Jonas ;
Bylock, Anders ;
Siegbahn, Agneta ;
Wallentin, Lars .
EUROPEAN HEART JOURNAL, 2007, 28 (06) :692-698
[9]   Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries [J].
Chung, Sheng-Chia ;
Sundstrom, Johan ;
Gale, Chris P. ;
James, Stefan ;
Deanfield, John ;
Wallentin, Lars ;
Timmis, Adam ;
Jernberg, Tomas ;
Hemingway, Harry .
BMJ-BRITISH MEDICAL JOURNAL, 2015, 351
[10]   The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT [J].
Cimenti, Christina ;
Koestenberger, Martin ;
Leschnik, Bettina ;
Haidl, Harald ;
Muntean, Wolfgang .
THROMBOSIS RESEARCH, 2007, 119 (03) :361-367